Mostrando 3 resultados de: 3
Subtipo de publicación
Article(3)
A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
ArticleAbstract: The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) hPalabras claves:Clinical trials as topic, COGNITION, Down syndrome, Intellectual disabilities, TESDAD neurocognitive batteryAutores:Benejam B., Blanco L., Blehaut H., Catuara-Solarz S., Civit E., Cuenca-Royo A.M., de Sola S., del Hoyo L., Dierssen M., Espadaler J.M., Farré M., Freixas R., Hernandez G., Ivan Dueñas-Espín, PhD, Langohr K., Legout V., Peña-Casanova J., Principe A., Pujol J., Roca L., Rodríguez J., Sanchez-Benavides G., Sánchez-Gutiérrez J., Torre R.d.l., Trias K., Videla S., Xicota L.Fuentes:googlescopusMultiple adverse drug reactions and genetic polymorphism testing
ArticleAbstract: Rationale: Defects in drug metabolic pathways could explain why some patients have a history of multPalabras claves:adverse drug reactions, CYP2D6, drug metabolism, genetic polymorphism, multiple drug intolerance syndromeAutores:Adrián LLerena, Arellano A.L., Farré M., Martin-Subero M., Monerris M., Montané E.Fuentes:scopusSafety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): A double-blind, randomised, placebo-controlled, phase 2 trial
ArticleAbstract: Background: Early cognitive intervention is the only routine therapeutic approach used for amelioratPalabras claves:Autores:Benejam B., Blanco-Hinojo L., Blehaut H., Catuara-Solarz S., Civit E., Cuenca-Royo A.M., de Sola S., del Hoyo L., Delabar J.M., Dierssen M., Espadaler J.M., Farré M., Fitó M., Freixas R., Hernandez G., Ivan Dueñas-Espín, PhD, Janel N., Langohr K., Legout V., Principe A., Pujol J., Roca L., Rodríguez J., Sanchez G., Sanchez-Benavides G., Sánchez-Gutiérrez J., Torre R.d.l., Trias K., Videla S., Xicota L.Fuentes:googlescopus